COVID-19 Rapid Antigen Test as Screening Strategy at Points of Entry: Experience in Lazio Region, Central Italy, August–October 2020

COVID-19 pandemic is a dramatic health, social and economic global challenge. There is urgent need to maximize testing capacity. Rapid Antigen Tests (RAT) represent good candidates for point-of-care and mass surveillance testing to rapidly identify SARS-CoV-2-infected people, counterbalancing lower...

Full description

Bibliographic Details
Main Authors: Francesca Colavita, Francesco Vairo, Silvia Meschi, Maria Beatrice Valli, Eleonora Lalle, Concetta Castilletti, Danilo Fusco, Giuseppe Spiga, Pierluigi Bartoletti, Simona Ursino, Maurizio Sanguinetti, Antonino Di Caro, Francesco Vaia, Giuseppe Ippolito, Maria Rosaria Capobianchi
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Biomolecules
Subjects:
Online Access:https://www.mdpi.com/2218-273X/11/3/425
id doaj-e70a5fb8342a4373a890a8489a95c791
record_format Article
spelling doaj-e70a5fb8342a4373a890a8489a95c7912021-03-14T00:04:06ZengMDPI AGBiomolecules2218-273X2021-03-011142542510.3390/biom11030425COVID-19 Rapid Antigen Test as Screening Strategy at Points of Entry: Experience in Lazio Region, Central Italy, August–October 2020Francesca Colavita0Francesco Vairo1Silvia Meschi2Maria Beatrice Valli3Eleonora Lalle4Concetta Castilletti5Danilo Fusco6Giuseppe Spiga7Pierluigi Bartoletti8Simona Ursino9Maurizio Sanguinetti10Antonino Di Caro11Francesco Vaia12Giuseppe Ippolito13Maria Rosaria Capobianchi14National Institute for Infectious Diseases, “Lazzaro Spallanzani” IRCCS, 00149 Rome, ItalyNational Institute for Infectious Diseases, “Lazzaro Spallanzani” IRCCS, 00149 Rome, ItalyNational Institute for Infectious Diseases, “Lazzaro Spallanzani” IRCCS, 00149 Rome, ItalyNational Institute for Infectious Diseases, “Lazzaro Spallanzani” IRCCS, 00149 Rome, ItalyNational Institute for Infectious Diseases, “Lazzaro Spallanzani” IRCCS, 00149 Rome, ItalyNational Institute for Infectious Diseases, “Lazzaro Spallanzani” IRCCS, 00149 Rome, ItalyLazio Regional Health Service, 00145 Rome, ItalyLazio Regional Health Service, 00145 Rome, ItalyRegional Special Unit for Community Health Care (USCAR), National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS, 00149 Rome, ItalyLocal Health Authority-Roma 4, Civitavecchia, 00153 Rome, ItalyFondazione Policlinico Universitario “A. Gemelli” IRCCS, 00168 Rome, ItalyNational Institute for Infectious Diseases, “Lazzaro Spallanzani” IRCCS, 00149 Rome, ItalyNational Institute for Infectious Diseases, “Lazzaro Spallanzani” IRCCS, 00149 Rome, ItalyNational Institute for Infectious Diseases, “Lazzaro Spallanzani” IRCCS, 00149 Rome, ItalyNational Institute for Infectious Diseases, “Lazzaro Spallanzani” IRCCS, 00149 Rome, ItalyCOVID-19 pandemic is a dramatic health, social and economic global challenge. There is urgent need to maximize testing capacity. Rapid Antigen Tests (RAT) represent good candidates for point-of-care and mass surveillance testing to rapidly identify SARS-CoV-2-infected people, counterbalancing lower sensitivity vs. gold standard molecular tests with fast results and possible recurrent testing. We describe the results obtained with the testing algorithm implemented at points of entry (airports and ports) in the Lazio Region (Italy), using the STANDARD F COVID-19 Antigen Fluorescence ImmunoAssay (FIA), followed by molecular confirmation of FIA-positive samples. From mid-August to mid-October 2020, 73,643 RAT were reported to the Regional Surveillance Information System for travelers at points of entry in Lazio Region. Of these, 1176 (1.6%) were FIA-positive, and the proportion of RT-PCR-confirmed samples was 40.5%. Our data show that the probability of confirmation was directly dependent from the semi-quantitative FIA results. In addition, the molecularly confirmed samples were those with high levels of virus and that were actually harboring infectious virus. These results support public health strategies based on early mass screening campaigns by RAT in settings where molecular testing is not feasible or easily accessible, such as points of entry. This approach would contribute to promptly controlling viral spread through travel, which is now of particular concern due to the spread of SARS-CoV-2 variants.https://www.mdpi.com/2218-273X/11/3/425SARS-CoV-2rapid antigen testpoint of entryItaly
collection DOAJ
language English
format Article
sources DOAJ
author Francesca Colavita
Francesco Vairo
Silvia Meschi
Maria Beatrice Valli
Eleonora Lalle
Concetta Castilletti
Danilo Fusco
Giuseppe Spiga
Pierluigi Bartoletti
Simona Ursino
Maurizio Sanguinetti
Antonino Di Caro
Francesco Vaia
Giuseppe Ippolito
Maria Rosaria Capobianchi
spellingShingle Francesca Colavita
Francesco Vairo
Silvia Meschi
Maria Beatrice Valli
Eleonora Lalle
Concetta Castilletti
Danilo Fusco
Giuseppe Spiga
Pierluigi Bartoletti
Simona Ursino
Maurizio Sanguinetti
Antonino Di Caro
Francesco Vaia
Giuseppe Ippolito
Maria Rosaria Capobianchi
COVID-19 Rapid Antigen Test as Screening Strategy at Points of Entry: Experience in Lazio Region, Central Italy, August–October 2020
Biomolecules
SARS-CoV-2
rapid antigen test
point of entry
Italy
author_facet Francesca Colavita
Francesco Vairo
Silvia Meschi
Maria Beatrice Valli
Eleonora Lalle
Concetta Castilletti
Danilo Fusco
Giuseppe Spiga
Pierluigi Bartoletti
Simona Ursino
Maurizio Sanguinetti
Antonino Di Caro
Francesco Vaia
Giuseppe Ippolito
Maria Rosaria Capobianchi
author_sort Francesca Colavita
title COVID-19 Rapid Antigen Test as Screening Strategy at Points of Entry: Experience in Lazio Region, Central Italy, August–October 2020
title_short COVID-19 Rapid Antigen Test as Screening Strategy at Points of Entry: Experience in Lazio Region, Central Italy, August–October 2020
title_full COVID-19 Rapid Antigen Test as Screening Strategy at Points of Entry: Experience in Lazio Region, Central Italy, August–October 2020
title_fullStr COVID-19 Rapid Antigen Test as Screening Strategy at Points of Entry: Experience in Lazio Region, Central Italy, August–October 2020
title_full_unstemmed COVID-19 Rapid Antigen Test as Screening Strategy at Points of Entry: Experience in Lazio Region, Central Italy, August–October 2020
title_sort covid-19 rapid antigen test as screening strategy at points of entry: experience in lazio region, central italy, august–october 2020
publisher MDPI AG
series Biomolecules
issn 2218-273X
publishDate 2021-03-01
description COVID-19 pandemic is a dramatic health, social and economic global challenge. There is urgent need to maximize testing capacity. Rapid Antigen Tests (RAT) represent good candidates for point-of-care and mass surveillance testing to rapidly identify SARS-CoV-2-infected people, counterbalancing lower sensitivity vs. gold standard molecular tests with fast results and possible recurrent testing. We describe the results obtained with the testing algorithm implemented at points of entry (airports and ports) in the Lazio Region (Italy), using the STANDARD F COVID-19 Antigen Fluorescence ImmunoAssay (FIA), followed by molecular confirmation of FIA-positive samples. From mid-August to mid-October 2020, 73,643 RAT were reported to the Regional Surveillance Information System for travelers at points of entry in Lazio Region. Of these, 1176 (1.6%) were FIA-positive, and the proportion of RT-PCR-confirmed samples was 40.5%. Our data show that the probability of confirmation was directly dependent from the semi-quantitative FIA results. In addition, the molecularly confirmed samples were those with high levels of virus and that were actually harboring infectious virus. These results support public health strategies based on early mass screening campaigns by RAT in settings where molecular testing is not feasible or easily accessible, such as points of entry. This approach would contribute to promptly controlling viral spread through travel, which is now of particular concern due to the spread of SARS-CoV-2 variants.
topic SARS-CoV-2
rapid antigen test
point of entry
Italy
url https://www.mdpi.com/2218-273X/11/3/425
work_keys_str_mv AT francescacolavita covid19rapidantigentestasscreeningstrategyatpointsofentryexperienceinlazioregioncentralitalyaugustoctober2020
AT francescovairo covid19rapidantigentestasscreeningstrategyatpointsofentryexperienceinlazioregioncentralitalyaugustoctober2020
AT silviameschi covid19rapidantigentestasscreeningstrategyatpointsofentryexperienceinlazioregioncentralitalyaugustoctober2020
AT mariabeatricevalli covid19rapidantigentestasscreeningstrategyatpointsofentryexperienceinlazioregioncentralitalyaugustoctober2020
AT eleonoralalle covid19rapidantigentestasscreeningstrategyatpointsofentryexperienceinlazioregioncentralitalyaugustoctober2020
AT concettacastilletti covid19rapidantigentestasscreeningstrategyatpointsofentryexperienceinlazioregioncentralitalyaugustoctober2020
AT danilofusco covid19rapidantigentestasscreeningstrategyatpointsofentryexperienceinlazioregioncentralitalyaugustoctober2020
AT giuseppespiga covid19rapidantigentestasscreeningstrategyatpointsofentryexperienceinlazioregioncentralitalyaugustoctober2020
AT pierluigibartoletti covid19rapidantigentestasscreeningstrategyatpointsofentryexperienceinlazioregioncentralitalyaugustoctober2020
AT simonaursino covid19rapidantigentestasscreeningstrategyatpointsofentryexperienceinlazioregioncentralitalyaugustoctober2020
AT mauriziosanguinetti covid19rapidantigentestasscreeningstrategyatpointsofentryexperienceinlazioregioncentralitalyaugustoctober2020
AT antoninodicaro covid19rapidantigentestasscreeningstrategyatpointsofentryexperienceinlazioregioncentralitalyaugustoctober2020
AT francescovaia covid19rapidantigentestasscreeningstrategyatpointsofentryexperienceinlazioregioncentralitalyaugustoctober2020
AT giuseppeippolito covid19rapidantigentestasscreeningstrategyatpointsofentryexperienceinlazioregioncentralitalyaugustoctober2020
AT mariarosariacapobianchi covid19rapidantigentestasscreeningstrategyatpointsofentryexperienceinlazioregioncentralitalyaugustoctober2020
_version_ 1724221739874910208